FierceBiotech 24 févr. 2026 Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
FierceBiotech 24 févr. 2026 Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months
FierceBiotech 24 févr. 2026 ‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
FierceBiotech 23 févr. 2026 UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
FierceBiotech 23 févr. 2026 Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail
FierceBiotech 23 févr. 2026 MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
FierceBiotech 23 févr. 2026 iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
FierceBiotech 20 févr. 2026 Ionis scraps early candidate for Alzheimer’s in people with Down syndrome
FierceBiotech 20 févr. 2026 Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint